Understanding how antibodies and vaccines can help treat HIV-1
Official title: Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
Funded at Beth Israel Deaconess Medical Center · NIH-11084511 · Data updated 2026-11-12
This study is looking at how certain antibodies and vaccines can help fight HIV-1 and keep the virus from coming back after treatment stops, with the hope that the findings will lead to better treatments and possibly a cure for people living with HIV.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 11, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,505,858 |
| NIH project number | 5P01AI177687-03 |
| Project ID | NIH-11084511 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living with HIV-1 who are currently on antiretroviral therapy.
✕Less likely to help
Patients who are not infected with HIV-1 or those who are not on antiretroviral therapy may not benefit from this research.
What this research studies
This research aims to explore how broadly neutralizing antibodies (bNAbs) and therapeutic vaccines can effectively combat HIV-1. By using advanced techniques to analyze immune responses and viral reservoirs in both humans and nonhuman primates, the study seeks to uncover the mechanisms that allow these treatments to delay viral rebound after stopping antiretroviral therapy. Patients may benefit from insights gained through this research, which could lead to improved strategies for HIV-1 treatment and potential cures.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and possibly a cure for HIV-1.
How similar studies have gone: Previous studies have shown promise in using similar approaches to enhance HIV treatment, indicating a potential for success in this research.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Barouch, Dan H. — Beth Israel Deaconess Medical Center
- Study coordinator: Barouch, Dan H.
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.